Biocon Stock Latest Update

Q4 FY25 Financial Results: Biocon reported strong Q4 FY25 results with a significant 153% year-on-year increase in consolidated net profit, reaching ₹344 crore. Revenue also saw a healthy 12% increase to ₹4,454 crore. USFDA Approval: Biocon Pharma, a wholly-owned subsidiary, received approval from the USFDA for its ANDA for Rivaroxaban Tablets USP. This medication is used to treat conditions like deep vein thrombosis and pulmonary embolism and to reduce the risk of stroke. Market Access for Yesintek™: Biocon Biologics has secured broad market access coverage in the United States for its biosimilar bUstekinumab (Yesintek™), covering over 100 million lives. Launch Permission for Yesafili™: Biocon Biologics also received permission to launch Yesafili™, an interchangeable biosimilar to Eylea® (a treatment for eye conditions), in the US market by 2026. Fundraising Plans: Biocon's board has approved a proposal to raise up to ₹4,500 crore through various means, including institutional placements or rights issues, to potentially increase its stake in its Biologics unit. Key Financial Metrics: P/E Ratio (TTM): Around 39.98 - 43.60 Price/Book Ratio: Approximately 1.88 - 1.89 Dividend Yield: Approximately 0.15% - 0.37% Shareholding Pattern (as of March 31, 2025): Promoters: 60.64% Foreign Institutional Investors (FII): 5.67% Mutual Funds: 8.77%